Also available in Persian — نسخه فارسی ✈️ Telegram EN فا
❓ Unknown

FDA approves new drug for advanced head and neck squamous cell carcinoma

Just now November 18, 2026 1 min read 📰 Medical Xpress
📋 Key Takeaway

The FDA approved Janssen Biotech's Rybrevant Faspro for treating advanced head and neck cancer in adults whose disease has progressed despite platinum-based chemotherapy and immunotherapy. This is a pharmaceutical development by a U.S. company with no direct connection to Iran.

The U.S. Food and Drug Administration has approved Janssen Biotech's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed during or after receipt of platinum-based chemotherapy and immunotherapy.

🌐

Translated from the original and edited for English readers. View original source →

Translation confidence: 100%

📰 Related Coverage

⚖️ Independent Platform — Artesh.com is not affiliated with any government, military, or political organization. Editorial Policy →